Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.53 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27576463 | 0.98 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Ammonia Solution, Strong SCHEMBL21518028 | 0.98 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Hydrochloric Acid SCHEMBL115247 | 0.98 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| SCHEMBL335044 | 0.96 | LOXL2 (0.69) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Bromide SCHEMBL11379599 | 0.94 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| SCHEMBL19874575 | 0.94 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Hydrochloric Acid SCHEMBL7504059 | 0.86 | LOXL2 (0.62) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| SCHEMBL20303796 | 0.85 | HPGD (0.58) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Hydrochloric Acid SCHEMBL17260639 | 0.85 | LOXL2 (0.60) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| SCHEMBL43299 | 0.84 | LOXL2 (0.64) | LOXL2TSHRIDO1ALDH1A1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960233-B1 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECH LTD (GB) | 2019-10-30 | — | — | EP | disclosed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20160355478-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9358222-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-07 | — | — | US | disclosed |
| EP-2960233-A1 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2015-12-30 | — | — | EP | disclosed |
| US-20140194486-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-07-10 | — | — | US | disclosed |
| US-8618158-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-12-31 | — | — | US | disclosed |
| US-20110224274-A1 | New Therapeutic Agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| EP-2315749-A2 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2009156735-A2 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-30 | — | — | WO | disclosed |
| US-7262172-B2 | Macrolides | GLAXO GROUP LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| US-20040254124-A1 | Macrolides | PLIVA D.D. (HR) | 2004-12-16 | — | — | US | disclosed |
| EP-1328535-A1 | MACROLIDES | GLAXO GROUP LIMITED (GB) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032917-A1 | MACROLIDES | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194486-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | KCNH2 4720/4885HRH3 3302/4885CA2 3974/4885 |
| US-20040254124-A1 | Macrolides | OGFOD1, TLR7, MALT1 | KCNH2 1816/4885HRH3 285/4885CA2 1031/4885 |
| US-20110224274-A1 | New Therapeutic Agents | TP53, MDM2, TP53BP1 | KCNH2 4701/4885HRH3 3299/4885CA2 4221/4885 |
| US-20180118684-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | KCNH2 4720/4885HRH3 3302/4885CA2 3974/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | KCNH2 4720/4885HRH3 3302/4885CA2 3974/4885 |
| US-20160355478-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | KCNH2 4720/4885HRH3 3302/4885CA2 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.